

# Jason M Pogue

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9470017/jason-m-pogue-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

3,544  
citations

33  
h-index

59  
g-index

100  
ext. papers

4,648  
ext. citations

4.8  
avg, IF

6.21  
L-index

#	Paper	IF	Citations
92	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of	5.8	280
91	Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 879-84	11.6	242
90	Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e445-e454	11.6	235
89	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa105	1	190
88	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	126
87	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , <b>2021</b> , 21, 213-225	25.5	108
86	Agents of Last Resort: Polymyxin Resistance. <i>Infectious Disease Clinics of North America</i> , <b>2016</b> , 30, 391-414	14.5	90
85	Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 519-524	11.6	88
84	Carbapenem-resistant <i>Acinetobacter baumannii</i> : epidemiology, surveillance and management. <i>Expert Review of Anti-Infective Therapy</i> , <b>2013</b> , 11, 383-93	5.5	81
83	1600. Susceptibility of $\beta$ -Lactam-Resistant <i>Pseudomonas aeruginosa</i> to Other $\beta$ -Lactams: Is There Truly a Lack of Cross-Resistance?. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S583-S584	1	78
82	2193. Factors Impacting the Duration of Antimicrobial Therapy for Community-Acquired Pneumonia. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S746-S747	1	78
81	522. In Vitro Antimicrobial Activity of Ceftazidime/Avibactam Compared with Ceftolozane/Tazobactam Against Real-world Clinical Isolates of <i>Pseudomonas aeruginosa</i> at a Large Academic Tertiary Care Hospital. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S251-S252	1	78
80	1106. Assessment of Fluoroquinolone Appropriateness for Hospitalized Patients with Asymptomatic Bacteriuria and Cystitis: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S393-S394	1	78
79	1083. Risk Factors Associated with Treatment of Asymptomatic Bacteriuria in the Emergency Department: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S384-S385	1	78
78	1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Bloodstream Infections (BSI). <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S582-S582	1	78
77	551. Burden of Illness in Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections in US Hospitals (2014 to 2018). <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S262-S262	1	78
76	1185. Impact of Utilizing Drug Resistance in Pneumonia (DRIP) Score on Management of Pneumonia. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S425-S425	1	78

75	1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for <i>P. aeruginosa</i> , <i>A. baumannii</i> , and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S559-S559	1	78
74	2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program and Rapid Genotypic Organism/Resistance Marker Identification. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S606-S606	1	78
73	1811. Minimizing Time to Optimal Therapy for Enterobacteriaceae Bloodstream Infections: Is Organism Identification Enough?. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S514-S514	1	78
72	1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against <i>Pseudomonas aeruginosa</i> (PA) as a Case Study. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S437-S437	1	78
71	1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S453-S454	1	78
70	2366. Treatment Characteristics and Predictors of Mortality in Patients With Infected Chronic Pressure Ulcers in Detroit. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S704-S704	1	78
69	2415. Comparison of Minocycline MIC <sub>B</sub> Obtained by Etest to Those Obtained by Broth Microdilution in a Bank of Isolates of <i>Acinetobacter baumannii</i> Collected in Southeastern Michigan. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S722-S722	1	78
68	Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. <i>Virulence</i> , <b>2017</b> , 8, 403-416	4.7	70
67	Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 304-310	11.6	63
66	Making the change to area under the curve-based vancomycin dosing. <i>American Journal of Health-System Pharmacy</i> , <b>2018</b> , 75, 1986-1995	2.2	53
65	Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 17-40	6.2	52
64	Automated alerts coupled with antimicrobial stewardship intervention lead to decreases in length of stay in patients with gram-negative bacteremia. <i>Infection Control and Hospital Epidemiology</i> , <b>2014</b> , 35, 132-8	2	47
63	Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant <i>A. baumannii</i> : A Review. <i>Infectious Diseases and Therapy</i> , <b>2017</b> , 6, 199-211	6.2	45
62	Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. <i>Drugs</i> , <b>2019</b> , 79, 243-269	12.1	41
61	Revisiting "older" antimicrobials in the era of multidrug resistance. <i>Pharmacotherapy</i> , <b>2011</b> , 31, 912-21	5.8	36
60	Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. <i>American Journal of Infection Control</i> , <b>2014</b> , 42, 612-20	3.8	34
59	Polymyxin B in combination with meropenem against carbapenemase-producing <i>Klebsiella pneumoniae</i> : pharmacodynamics and morphological changes. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 49, 224-232	14.3	32
58	Tocilizumab for treatment of mechanically ventilated patients with COVID-19 <b>2020</b> ,		28

57	An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	26
56	Risk factors for bloodstream infection caused by extended-spectrum $\beta$ -lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : A focus on antimicrobials including cefepime. <i>American Journal of Infection Control</i> , <b>2015</b> , 43, 719-23	3.8	24
55	Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant <i>Enterococcus</i> , Detroit, 2008-10. <i>Journal of Antibiotics</i> , <b>2013</b> , 66, 625-7	3.7	24
54	The Verigene dilemma: gram-negative polymicrobial bloodstream infections and clinical decision making. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2018</b> , 91, 144-146	2.9	21
53	Intravenous fosfomycin for the treatment of hospitalized patients with serious infections. <i>Expert Review of Anti-Infective Therapy</i> , <b>2017</b> , 15, 935-945	5.5	21
52	Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3968-75	5.9	20
51	Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?. <i>International Journal of Antimicrobial Agents</i> , <b>2016</b> , 48, 622-626	14.3	19
50	Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	18
49	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. <i>Clinical Microbiology and Infection</i> , <b>2021</b> ,	9.5	18
48	Nephrotoxicity comparison of two commercially available generic vancomycin products. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 5470-4	5.9	15
47	Role of unit-specific combination antibiograms for improving the selection of appropriate empiric therapy for gram-negative pneumonia. <i>Infection Control and Hospital Epidemiology</i> , <b>2011</b> , 32, 289-92	2	15
46	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 561-572	6.2	15
45	Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum $\beta$ -lactamase-producing <i>Klebsiella pneumoniae</i> . <i>American Journal of Infection Control</i> , <b>2011</b> , 39, 390-395	3.8	14
44	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 525-536	6.2	14
43	Critical Need for Clarity in Polymyxin B Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	11
42	Antibiotic Overuse After Hospital Discharge: A Multi-hospital Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e4499-e4506	11.6	10
41	Is there really no benefit to combination therapy with colistin?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2013</b> , 11, 881-4	5.5	9
40	Assessment of Combined Polymyxin B and Minocycline Therapy against <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-Producing <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	8

39	Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, S223-S232	11.6	8
38	The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa161	1	8
37	Toxicity in Patients. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1145, 289-304	3.6	7
36	Agents of Last Resort: An Update on Polymyxin Resistance. <i>Infectious Disease Clinics of North America</i> , <b>2020</b> , 34, 723-750	6.5	7
35	The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals. <i>Hospital Pharmacy</i> , <b>2015</b> , 50, 180-4	1.1	6
34	Antimicrobial Stewardship for the Infection Control Practitioner. <i>Infectious Disease Clinics of North America</i> , <b>2016</b> , 30, 771-84	6.5	6
33	Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant <i>Serratia marcescens</i> and <i>Enterobacter aerogenes</i> bacteraemia in a haemodialysis patient. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 3529-3531	5.1	6
32	Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , <b>2019</b> , 8, 199-208	6.2	5
31	Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 2405-2410	5.1	5
30	Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab434	1	5
29	Assessment of Testing and Treatment of Asymptomatic Bacteriuria Initiated in the Emergency Department. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa537	1	4
28	Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 3033-3041	11.6	4
27	Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics Tests. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa278	1	4
26	Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. <i>Journal of Infection and Public Health</i> , <b>2014</b> , 7, 50-3	7.4	3
25	Extended-spectrum $\beta$ -lactamase-producing <i>Escherichia coli</i> isolation among older adults: epidemiology and outcomes. <i>American Journal of Infection Control</i> , <b>2014</b> , 42, 565-8	3.8	3
24	Carbapenem-Susceptible <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> Isolates Carrying a Truncated KPC Carbapenemase: a Challenge for Rapid Molecular Diagnostics. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	3
23	Asymptomatic bacterisputia: Rethinking diagnostic stewardship in pneumonia. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 42, 737-739	2	3
22	Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa084	1	2

21	Burden of illness in carbapenem-resistant <i>Acinetobacter baumannii</i> infections in US hospitals between 2014 and 2019.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 36	4	2
20	Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab268	1	2
19	1562. Safety and Efficacy of High-Dose Cefazolin Therapy in Obesity. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S570-S570	1	2
18	521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S251-S251	1	2
17	The Clinical Impact of a Negative Molecular $\beta$ -Lactamase Gene Test for : Let's Not Let Perfect Be the Enemy of Really Good. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	1
16	ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. <i>JMIR MHealth and UHealth</i> , <b>2020</b> , 8, e20525	5.5	1
15	Reply to Vena et al. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1801-1802	11.6	1
14	Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia Coli</i> Infections in Metro Detroit: Early Dominance of the ST-131 Clone. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 683-690	6.2	1
13	2406. Real-world Treatment of Multidrug-Resistant (MDR) or Extensively Drug-Resistant (XDR) <i>P. aeruginosa</i> Infections With Ceftolozane/Tazobactam (C/T) vs. a Polymyxin or Aminoglycoside (Poly/AG)-based Regimen: A Multicenter Comparative Effectiveness Study. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S719-S719	1	1
12	842. Impact of Active Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections in US Hospitals Between 2014 and 2019. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S462-S462	1	0
11	2890. Antibiotic Overuse at Discharge in Hospitalized Patients with Bacteriuria or Treated for Pneumonia: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S78-S79	1	0
10	Antimicrobial Stewardship and the Infection Control Practitioner: A Natural Alliance. <i>Infectious Disease Clinics of North America</i> , <b>2021</b> , 35, 771-787	6.5	0
9	Recommended Revisions to the National SEP-1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. <i>Pharmacotherapy</i> , <b>2020</b> , 40, 368-371	5.8	
8	Reply to Manian. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 178-179	11.6	
7	642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S423-S423	1	
6	1117. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S651-S651	1	
5	848. Trends of Carbapenem Resistance in Enterobacterales in the US Between 2015 and 2019. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S464-S464	1	
4	The role of tazobactam-based combinations for the management of infections due to extended-spectrum $\beta$ -lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , <b>2021</b> , 41, 864-880	5.8	

- 3 630. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem. *Open Forum Infectious Diseases*, **2021**, 8, S418-S419 1
- 2 786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) *Pseudomonas aeruginosa* (PSA) From 2016-2019: A Multicenter Evaluation. *Open Forum Infectious Diseases*, **2021**, 8, S490-S490 1
- 1 638. The Impact of in vitro Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-resistant Gram-negative Infections: A Report from the OVERCOME Trial. *Open Forum Infectious Diseases*, **2021**, 8, S421-S422 1